179 related articles for article (PubMed ID: 33868667)
1. Pharmacological, Endoscopic, Metabolic, and Surgical Procedures for Nonalcoholic Fatty Liver Disease.
Xanthakos SA
Clin Liver Dis (Hoboken); 2021 Mar; 17(3):209-214. PubMed ID: 33868667
[No Abstract] [Full Text] [Related]
2. Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks.
Ren M; Zhou X; Lv L; Ji F
J Clin Transl Hepatol; 2022 Oct; 10(5):986-994. PubMed ID: 36304503
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.
Lonardo A; Ballestri S; Marchesini G; Angulo P; Loria P
Dig Liver Dis; 2015 Mar; 47(3):181-90. PubMed ID: 25739820
[TBL] [Abstract][Full Text] [Related]
4. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Fatty Liver Disease and Continuous Metabolic Syndrome in Adolescents with Overweight/Obesity.
Ferreira S; Mendes J; Couto D; Ferreira D; Rêgo C
Acta Med Port; 2024 Mar; 37(3):177-186. PubMed ID: 38330918
[TBL] [Abstract][Full Text] [Related]
6. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
[TBL] [Abstract][Full Text] [Related]
7. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.
Hamaguchi M; Kojima T; Takeda N; Nakagawa T; Taniguchi H; Fujii K; Omatsu T; Nakajima T; Sarui H; Shimazaki M; Kato T; Okuda J; Ida K
Ann Intern Med; 2005 Nov; 143(10):722-8. PubMed ID: 16287793
[TBL] [Abstract][Full Text] [Related]
8. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.
Yang S; Kwak S; Lee JH; Kang S; Lee SP
PLoS One; 2019; 14(11):e0224626. PubMed ID: 31682638
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.
Federico A; Dallio M; Masarone M; Gravina AG; Di Sarno R; Tuccillo C; Cossiga V; Lama S; Stiuso P; Morisco F; Persico M; Loguercio C
Oxid Med Cell Longev; 2019; 2019():8742075. PubMed ID: 31737175
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Prasoppokakorn T; Pitisuttithum P; Treeprasertsuk S
J Clin Transl Hepatol; 2021 Dec; 9(6):939-946. PubMed ID: 34966657
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.
Bisaccia G; Ricci F; Mantini C; Tana C; Romani GL; Schiavone C; Gallina S
SAGE Open Med; 2020; 8():2050312120933804. PubMed ID: 32612827
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease.
Pereira ENGDS; Silvares RR; Flores EEI; Rodrigues KL; Daliry A
Microcirculation; 2020 Apr; 27(3):e12603. PubMed ID: 31876010
[TBL] [Abstract][Full Text] [Related]
14. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease.
Dumas ME; Kinross J; Nicholson JK
Gastroenterology; 2014 Jan; 146(1):46-62. PubMed ID: 24211299
[TBL] [Abstract][Full Text] [Related]
15. Moderation Effect of Handgrip Strength on the Associations of Obesity and Metabolic Syndrome With Fatty Liver in Adolescents.
Lee K
J Clin Densitom; 2020; 23(2):278-285. PubMed ID: 31060787
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss.
Popov VB; Lim JK
J Clin Transl Hepatol; 2015 Sep; 3(3):230-8. PubMed ID: 26623270
[TBL] [Abstract][Full Text] [Related]
17. Fatty liver and the metabolic syndrome.
Neuschwander-Tetri BA
Curr Opin Gastroenterol; 2007 Mar; 23(2):193-8. PubMed ID: 17268250
[TBL] [Abstract][Full Text] [Related]
18. A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose.
Jiang W; Jin Q; Li C; Xun Y
Turk J Gastroenterol; 2023 Nov; ():. PubMed ID: 37966266
[TBL] [Abstract][Full Text] [Related]
19. A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose.
Jiang W; Jin Q; Li C; Xun Y
Turk J Gastroenterol; 2024 Feb; 35(2):125-135. PubMed ID: 38454244
[TBL] [Abstract][Full Text] [Related]
20. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.
Kuraji R; Sekino S; Kapila Y; Numabe Y
Periodontol 2000; 2021 Oct; 87(1):204-240. PubMed ID: 34463983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
